APONTIS PHARMA AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.22 EUR | +3.01% |
|
+6.51% | +74.79% |
| Apr. 05 | Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications | MT |
| Mar. 28 | Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 177
Sales per Business
| EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
|---|---|---|---|---|---|
Single Pills - Hypertension
65.6
%
| 31 | 61.5 % | 37 | 65.6 % | +16.16% |
Co-Marketing - CO PD (Respiratory Diseases)
17.9
%
| 10 | 18.6 % | 10 | 17.9 % | +4.73% |
Co-Marketing - Diabetes
12.3
%
| 8 | 14.9 % | 7 | 12.3 % | -10.30% |
Corporate Brands (without Single Pills) - Other
3.8
%
| 2 | 3.9 % | 2 | 3.8 % | +7.51% |
Corporate Brands (without Single Pills) - Gynecology
0.5
%
| 1 | 1.2 % | 0 | 0.5 % | -55.95% |
Corporate Brands (without Single Pills) - Vascular
0.0
%
| 0 | 0.0 % | 0 | 0.0 % | -150.00% |
Sales per region
| EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
|---|---|---|---|---|---|
Germany
100.0
%
| 51 | 100.0 % | 56 | 100.0 % | +8.87% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | - | |
| Director of Finance/CFO | - | 21-12-31 | |
Olaf Randerath
CTO | Chief Tech/Sci/R&D Officer | - | - |
Sven Pauly
IRC | Investor Relations Contact | - | - |
Sanjeev Gotru
PRN | Corporate Officer/Principal | - | - |
Susanne Endreß
LAW | General Counsel | - | - |
Harald Weyand
SAM | Sales & Marketing | - | - |
Matthias Wendl
SAM | Sales & Marketing | - | - |
Thomas Milz
PRN | Corporate Officer/Principal | 59 | 20-12-31 |
Susanne Böhme
HRO | Human Resources Officer | - | - |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Edin Hadzic
BRD | Director/Board Member | 53 | 20-12-31 |
Olaf Elbracht
BRD | Director/Board Member | 59 | 20-12-31 |
| Chairman | 51 | 20-12-31 | |
| Director/Board Member | 39 | 20-12-31 | |
| Director/Board Member | - | 22-04-30 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 8,500,000 | 8,330,000 ( 98.00 %) | 170,000 ( 2.000 %) | 98.00 % |
Company contact information
APONTIS PHARMA AG
Alfred-Nobel-Strasse 10
40789, Monheim am Rhein
+49 2173 8955 4949
https://www.apontis-pharma.de
Sector
Sales per Business
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.32
EUR
Average target price
17.5
EUR
Spread / Average Target
+110.34%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +24.67% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +13.11% | 233B | |
| +5.44% | 201B | |
| -9.98% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B |
- Stock Market
- Equities
- APPH Stock
- APPH Stock
- Company Apontis Pharma AG
